Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Botswana | 150 | 2025 | 1065 | 4.900 |
Why?
|
HIV Infections | 173 | 2025 | 17591 | 4.070 |
Why?
|
HIV-1 | 79 | 2024 | 6962 | 2.950 |
Why?
|
Pregnancy Complications, Infectious | 44 | 2025 | 2190 | 2.280 |
Why?
|
Anti-HIV Agents | 56 | 2024 | 4576 | 2.100 |
Why?
|
Anti-Retroviral Agents | 32 | 2023 | 1795 | 1.790 |
Why?
|
Infectious Disease Transmission, Vertical | 29 | 2024 | 1360 | 1.490 |
Why?
|
Viral Load | 41 | 2024 | 3398 | 1.420 |
Why?
|
HIV Seropositivity | 15 | 2024 | 967 | 1.330 |
Why?
|
Antiretroviral Therapy, Highly Active | 32 | 2024 | 1903 | 1.220 |
Why?
|
Drug Resistance, Viral | 16 | 2024 | 869 | 1.150 |
Why?
|
Premature Birth | 17 | 2025 | 1830 | 1.080 |
Why?
|
Circumcision, Male | 6 | 2020 | 148 | 1.070 |
Why?
|
RNA, Viral | 26 | 2021 | 2871 | 0.980 |
Why?
|
Heterocyclic Compounds, 3-Ring | 6 | 2024 | 296 | 0.860 |
Why?
|
Zidovudine | 18 | 2024 | 625 | 0.850 |
Why?
|
Hepatitis B | 7 | 2024 | 711 | 0.780 |
Why?
|
Benzoxazines | 9 | 2024 | 321 | 0.770 |
Why?
|
Breast Feeding | 16 | 2023 | 1364 | 0.740 |
Why?
|
Pregnancy Outcome | 19 | 2025 | 2974 | 0.720 |
Why?
|
CD4 Lymphocyte Count | 30 | 2023 | 2598 | 0.710 |
Why?
|
Nevirapine | 14 | 2024 | 273 | 0.680 |
Why?
|
Reverse Transcriptase Inhibitors | 8 | 2020 | 622 | 0.650 |
Why?
|
HIV | 14 | 2023 | 1597 | 0.650 |
Why?
|
Pregnancy | 74 | 2025 | 30265 | 0.600 |
Why?
|
Hepatitis B virus | 8 | 2024 | 533 | 0.590 |
Why?
|
Stillbirth | 12 | 2024 | 381 | 0.570 |
Why?
|
Oxazines | 7 | 2024 | 358 | 0.530 |
Why?
|
Infant, Newborn | 52 | 2025 | 26428 | 0.510 |
Why?
|
Phylogeny | 14 | 2024 | 2843 | 0.480 |
Why?
|
Pyridones | 8 | 2024 | 819 | 0.460 |
Why?
|
HIV Antibodies | 13 | 2024 | 1341 | 0.460 |
Why?
|
Alkynes | 9 | 2024 | 327 | 0.460 |
Why?
|
Lamivudine | 6 | 2024 | 367 | 0.450 |
Why?
|
Genotype | 19 | 2024 | 13048 | 0.450 |
Why?
|
Cyclopropanes | 9 | 2024 | 437 | 0.440 |
Why?
|
HIV Integrase Inhibitors | 5 | 2024 | 165 | 0.410 |
Why?
|
Mass Screening | 6 | 2020 | 5457 | 0.390 |
Why?
|
Female | 157 | 2025 | 397515 | 0.380 |
Why?
|
Adult | 114 | 2025 | 223851 | 0.370 |
Why?
|
DNA, Viral | 11 | 2023 | 2205 | 0.370 |
Why?
|
Maternal-Fetal Exchange | 3 | 2018 | 456 | 0.370 |
Why?
|
Herpes Genitalis | 6 | 2011 | 149 | 0.350 |
Why?
|
Humans | 193 | 2025 | 768970 | 0.340 |
Why?
|
Proviruses | 5 | 2023 | 320 | 0.340 |
Why?
|
Infant Formula | 5 | 2021 | 195 | 0.330 |
Why?
|
Sexual Partners | 7 | 2018 | 807 | 0.330 |
Why?
|
Pregnancy Complications | 5 | 2023 | 2974 | 0.320 |
Why?
|
Child Development | 6 | 2019 | 2336 | 0.320 |
Why?
|
Hepatitis B, Chronic | 2 | 2023 | 413 | 0.320 |
Why?
|
Prenatal Exposure Delayed Effects | 7 | 2024 | 2542 | 0.310 |
Why?
|
Prevalence | 24 | 2024 | 15879 | 0.310 |
Why?
|
Hepatitis Delta Virus | 2 | 2024 | 24 | 0.300 |
Why?
|
Young Adult | 46 | 2025 | 60131 | 0.290 |
Why?
|
Infant | 35 | 2024 | 36556 | 0.290 |
Why?
|
Herpesvirus 2, Human | 6 | 2011 | 191 | 0.290 |
Why?
|
Mining | 1 | 2007 | 93 | 0.280 |
Why?
|
Viremia | 4 | 2024 | 725 | 0.280 |
Why?
|
Milk, Human | 5 | 2012 | 490 | 0.270 |
Why?
|
Piperazines | 6 | 2024 | 2553 | 0.270 |
Why?
|
Neural Tube Defects | 2 | 2019 | 255 | 0.270 |
Why?
|
Disease Transmission, Infectious | 3 | 2019 | 560 | 0.260 |
Why?
|
Incidence | 16 | 2024 | 21547 | 0.260 |
Why?
|
Acyclovir | 4 | 2011 | 267 | 0.260 |
Why?
|
Dietary Supplements | 4 | 2025 | 3443 | 0.260 |
Why?
|
Uterine Cervical Dysplasia | 2 | 2023 | 392 | 0.240 |
Why?
|
Hepatitis D | 1 | 2024 | 23 | 0.240 |
Why?
|
Prenatal Care | 2 | 2024 | 1162 | 0.240 |
Why?
|
Mutation | 12 | 2024 | 30266 | 0.230 |
Why?
|
Maternal Mortality | 2 | 2024 | 310 | 0.230 |
Why?
|
Male | 87 | 2024 | 365203 | 0.220 |
Why?
|
Wolves | 1 | 2023 | 10 | 0.220 |
Why?
|
Folic Acid | 3 | 2025 | 1338 | 0.210 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2024 | 4056 | 0.210 |
Why?
|
Dog Diseases | 1 | 2023 | 143 | 0.200 |
Why?
|
Dideoxynucleosides | 2 | 2012 | 135 | 0.200 |
Why?
|
Iron | 3 | 2025 | 1814 | 0.190 |
Why?
|
Epidemics | 2 | 2022 | 517 | 0.190 |
Why?
|
Occupational Health | 1 | 2007 | 812 | 0.180 |
Why?
|
Hepatitis B Surface Antigens | 4 | 2023 | 294 | 0.180 |
Why?
|
Adolescent | 30 | 2025 | 89244 | 0.180 |
Why?
|
Leukocytes, Mononuclear | 3 | 2023 | 1855 | 0.180 |
Why?
|
HIV Reverse Transcriptase | 2 | 2019 | 214 | 0.170 |
Why?
|
Rotavirus Vaccines | 1 | 2020 | 62 | 0.170 |
Why?
|
Anemia | 2 | 2025 | 1517 | 0.170 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2014 | 664 | 0.170 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2011 | 215 | 0.170 |
Why?
|
Mothers | 5 | 2024 | 2209 | 0.170 |
Why?
|
Pneumonia, Pneumococcal | 1 | 2020 | 133 | 0.170 |
Why?
|
Insulin Resistance | 2 | 2024 | 3982 | 0.170 |
Why?
|
Disease Reservoirs | 1 | 2019 | 123 | 0.160 |
Why?
|
Postpartum Period | 4 | 2017 | 1198 | 0.160 |
Why?
|
HIV Antigens | 2 | 2018 | 328 | 0.160 |
Why?
|
Antiviral Agents | 6 | 2024 | 3070 | 0.160 |
Why?
|
Vaccines, Conjugate | 1 | 2020 | 334 | 0.160 |
Why?
|
Treatment Failure | 7 | 2024 | 2664 | 0.160 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 3 | 2023 | 381 | 0.160 |
Why?
|
HIV Seronegativity | 2 | 2011 | 210 | 0.160 |
Why?
|
Paternal Exposure | 1 | 2019 | 101 | 0.160 |
Why?
|
Hepatitis B Antibodies | 3 | 2023 | 156 | 0.160 |
Why?
|
Drug Therapy, Combination | 11 | 2019 | 6320 | 0.160 |
Why?
|
Quarantine | 1 | 2020 | 186 | 0.150 |
Why?
|
Rural Population | 5 | 2024 | 2325 | 0.150 |
Why?
|
Obstetric Labor, Premature | 1 | 2020 | 268 | 0.150 |
Why?
|
Middle Aged | 42 | 2024 | 223737 | 0.150 |
Why?
|
Pregnant Women | 4 | 2024 | 576 | 0.150 |
Why?
|
Tuberculosis | 3 | 2019 | 2029 | 0.140 |
Why?
|
Virus Activation | 1 | 2019 | 324 | 0.140 |
Why?
|
Molecular Epidemiology | 1 | 2019 | 473 | 0.140 |
Why?
|
Transients and Migrants | 1 | 2020 | 170 | 0.140 |
Why?
|
Receptors, CXCR4 | 2 | 2012 | 729 | 0.140 |
Why?
|
Pneumococcal Vaccines | 1 | 2020 | 414 | 0.140 |
Why?
|
Papillomavirus Infections | 2 | 2023 | 1640 | 0.140 |
Why?
|
Qualitative Research | 3 | 2024 | 3143 | 0.140 |
Why?
|
Enzyme Assays | 1 | 2017 | 103 | 0.140 |
Why?
|
Syphilis | 1 | 2019 | 243 | 0.140 |
Why?
|
Pyridazines | 1 | 2018 | 203 | 0.130 |
Why?
|
Gestational Age | 2 | 2018 | 3621 | 0.130 |
Why?
|
Diarrhea, Infantile | 1 | 2016 | 100 | 0.130 |
Why?
|
Disease Progression | 8 | 2017 | 13674 | 0.130 |
Why?
|
Fetus | 2 | 2020 | 1882 | 0.130 |
Why?
|
Genes, env | 2 | 2013 | 95 | 0.130 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 2014 | 2203 | 0.130 |
Why?
|
Cervix Uteri | 1 | 2020 | 577 | 0.130 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 283 | 0.130 |
Why?
|
Congenital Abnormalities | 2 | 2019 | 704 | 0.130 |
Why?
|
Antimalarials | 1 | 2022 | 909 | 0.130 |
Why?
|
Serologic Tests | 1 | 2018 | 382 | 0.130 |
Why?
|
Antibody Affinity | 1 | 2016 | 253 | 0.130 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2021 | 529 | 0.120 |
Why?
|
Antibodies, Neutralizing | 5 | 2024 | 2009 | 0.120 |
Why?
|
Pregnancy, Unplanned | 1 | 2016 | 86 | 0.120 |
Why?
|
Nervous System | 1 | 2018 | 546 | 0.120 |
Why?
|
Asymptomatic Infections | 1 | 2015 | 136 | 0.120 |
Why?
|
Vascular Diseases | 1 | 2023 | 1163 | 0.120 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2017 | 337 | 0.110 |
Why?
|
Contraception Behavior | 1 | 2016 | 187 | 0.110 |
Why?
|
Diarrhea | 1 | 2020 | 1320 | 0.110 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2023 | 4413 | 0.110 |
Why?
|
Deficiency Diseases | 1 | 2013 | 74 | 0.110 |
Why?
|
Feasibility Studies | 2 | 2021 | 5323 | 0.110 |
Why?
|
Travel | 1 | 2019 | 805 | 0.110 |
Why?
|
Hepatitis B e Antigens | 2 | 2023 | 135 | 0.110 |
Why?
|
Causality | 1 | 2019 | 1256 | 0.110 |
Why?
|
Child | 16 | 2024 | 80960 | 0.110 |
Why?
|
Respiratory System | 1 | 2016 | 565 | 0.100 |
Why?
|
AIDS Serodiagnosis | 2 | 2020 | 220 | 0.100 |
Why?
|
Immunoassay | 1 | 2016 | 746 | 0.100 |
Why?
|
Malaria | 1 | 2022 | 1249 | 0.100 |
Why?
|
Vaccination | 2 | 2023 | 3438 | 0.100 |
Why?
|
Amino Acid Substitution | 3 | 2011 | 1742 | 0.100 |
Why?
|
Hypertension | 3 | 2023 | 8617 | 0.100 |
Why?
|
Immunity, Innate | 3 | 2022 | 3080 | 0.100 |
Why?
|
Mastitis | 1 | 2012 | 42 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2017 | 1194 | 0.100 |
Why?
|
HIV Envelope Protein gp120 | 3 | 2016 | 925 | 0.100 |
Why?
|
Plasma | 1 | 2015 | 585 | 0.100 |
Why?
|
Proportional Hazards Models | 5 | 2019 | 12562 | 0.100 |
Why?
|
Counseling | 2 | 2022 | 1554 | 0.100 |
Why?
|
Birth Weight | 3 | 2023 | 2121 | 0.100 |
Why?
|
Placental Insufficiency | 1 | 2012 | 50 | 0.100 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7478 | 0.100 |
Why?
|
Hemoglobins | 1 | 2018 | 1531 | 0.100 |
Why?
|
Secondary Prevention | 1 | 2018 | 1476 | 0.100 |
Why?
|
Evolution, Molecular | 2 | 2011 | 1894 | 0.100 |
Why?
|
Equipment and Supplies | 1 | 2014 | 274 | 0.090 |
Why?
|
Infant, Small for Gestational Age | 3 | 2021 | 468 | 0.090 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 620 | 0.090 |
Why?
|
Attitude to Health | 1 | 2020 | 2025 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3215 | 0.090 |
Why?
|
Hospitalization | 6 | 2021 | 10847 | 0.090 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2023 | 2044 | 0.090 |
Why?
|
Carotid Artery Diseases | 1 | 2017 | 878 | 0.090 |
Why?
|
Cross-Sectional Studies | 11 | 2023 | 26395 | 0.090 |
Why?
|
Selenium | 1 | 2013 | 418 | 0.090 |
Why?
|
Immunoglobulin M | 3 | 2023 | 1528 | 0.090 |
Why?
|
Prospective Studies | 14 | 2023 | 54962 | 0.090 |
Why?
|
Micronutrients | 2 | 2025 | 390 | 0.090 |
Why?
|
Condoms | 3 | 2022 | 338 | 0.090 |
Why?
|
Drug Resistance, Bacterial | 1 | 2017 | 1063 | 0.090 |
Why?
|
AIDS Vaccines | 1 | 2016 | 900 | 0.080 |
Why?
|
Developmental Disabilities | 2 | 2016 | 1520 | 0.080 |
Why?
|
Drug Administration Schedule | 5 | 2018 | 4862 | 0.080 |
Why?
|
Didanosine | 1 | 2009 | 151 | 0.080 |
Why?
|
Valine | 1 | 2011 | 410 | 0.080 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1281 | 0.080 |
Why?
|
Mutation, Missense | 3 | 2013 | 2592 | 0.080 |
Why?
|
Cytokines | 2 | 2015 | 7453 | 0.080 |
Why?
|
Child, Preschool | 10 | 2024 | 42683 | 0.080 |
Why?
|
Alphapapillomavirus | 1 | 2011 | 219 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2019 | 7861 | 0.080 |
Why?
|
Risk Factors | 17 | 2024 | 74976 | 0.080 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1240 | 0.080 |
Why?
|
Cohort Studies | 13 | 2021 | 41808 | 0.080 |
Why?
|
Sequence Analysis, DNA | 7 | 2015 | 4785 | 0.080 |
Why?
|
Intention to Treat Analysis | 3 | 2016 | 417 | 0.080 |
Why?
|
Health Services Research | 2 | 2019 | 1818 | 0.070 |
Why?
|
Directive Counseling | 1 | 2009 | 171 | 0.070 |
Why?
|
Case-Control Studies | 8 | 2021 | 22296 | 0.070 |
Why?
|
Receptors, Cell Surface | 1 | 2017 | 2820 | 0.070 |
Why?
|
Longitudinal Studies | 8 | 2020 | 14794 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 6 | 2016 | 6547 | 0.070 |
Why?
|
Hospitals, District | 2 | 2019 | 114 | 0.070 |
Why?
|
Health Services Accessibility | 3 | 2024 | 5522 | 0.070 |
Why?
|
Public Health | 1 | 2020 | 2680 | 0.070 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2014 | 843 | 0.070 |
Why?
|
Antigens, CD | 1 | 2017 | 4032 | 0.070 |
Why?
|
Patient Compliance | 5 | 2010 | 2701 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2021 | 9264 | 0.070 |
Why?
|
Acidosis, Lactic | 1 | 2007 | 145 | 0.070 |
Why?
|
Genetic Linkage | 1 | 2011 | 2342 | 0.070 |
Why?
|
Africa | 3 | 2017 | 726 | 0.060 |
Why?
|
Nitriles | 2 | 2023 | 990 | 0.060 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 2 | 2018 | 41 | 0.060 |
Why?
|
Social Perception | 1 | 2009 | 433 | 0.060 |
Why?
|
Truth Disclosure | 1 | 2009 | 433 | 0.060 |
Why?
|
Vitamins | 1 | 2013 | 1638 | 0.060 |
Why?
|
Models, Statistical | 1 | 2020 | 5110 | 0.060 |
Why?
|
Retrospective Studies | 12 | 2023 | 81903 | 0.060 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1388 | 0.060 |
Why?
|
Population Surveillance | 3 | 2019 | 2597 | 0.060 |
Why?
|
Stereotyping | 1 | 2006 | 241 | 0.060 |
Why?
|
Pneumonia | 1 | 2016 | 2164 | 0.060 |
Why?
|
Diagnostic Tests, Routine | 2 | 2020 | 790 | 0.060 |
Why?
|
Double-Blind Method | 5 | 2021 | 12467 | 0.060 |
Why?
|
Pregnancy Rate | 1 | 2007 | 655 | 0.060 |
Why?
|
Acetic Acid | 1 | 2023 | 59 | 0.060 |
Why?
|
Neonatal Screening | 2 | 2020 | 619 | 0.060 |
Why?
|
Time Factors | 9 | 2019 | 40261 | 0.060 |
Why?
|
Pre-Eclampsia | 1 | 2013 | 1255 | 0.050 |
Why?
|
Hepatitis B Core Antigens | 1 | 2023 | 90 | 0.050 |
Why?
|
RNA | 2 | 2023 | 2727 | 0.050 |
Why?
|
Tropism | 1 | 2023 | 44 | 0.050 |
Why?
|
Parturition | 2 | 2019 | 456 | 0.050 |
Why?
|
Heterosexuality | 2 | 2019 | 309 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2018 | 4544 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2013 | 3232 | 0.050 |
Why?
|
Colposcopy | 1 | 2023 | 151 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
HIV Protease Inhibitors | 2 | 2018 | 432 | 0.050 |
Why?
|
Withholding Treatment | 2 | 2019 | 620 | 0.050 |
Why?
|
Diketopiperazines | 1 | 2022 | 24 | 0.050 |
Why?
|
Infant Mortality | 3 | 2014 | 754 | 0.050 |
Why?
|
Viral Tropism | 1 | 2023 | 102 | 0.050 |
Why?
|
Genome, Viral | 2 | 2020 | 673 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2022 | 2211 | 0.050 |
Why?
|
Microbial Sensitivity Tests | 2 | 2018 | 1967 | 0.050 |
Why?
|
Workplace | 1 | 2007 | 873 | 0.050 |
Why?
|
Americas | 1 | 2021 | 110 | 0.050 |
Why?
|
Chloroquine | 1 | 2022 | 276 | 0.050 |
Why?
|
Vitamin D | 1 | 2014 | 3311 | 0.050 |
Why?
|
E-Selectin | 1 | 2023 | 578 | 0.040 |
Why?
|
Treatment Outcome | 11 | 2018 | 65480 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 2 | 2014 | 3235 | 0.040 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2023 | 692 | 0.040 |
Why?
|
Feces | 2 | 2017 | 1510 | 0.040 |
Why?
|
Immunoenzyme Techniques | 2 | 2013 | 1705 | 0.040 |
Why?
|
Databases, Nucleic Acid | 1 | 2021 | 204 | 0.040 |
Why?
|
Interviews as Topic | 2 | 2024 | 2744 | 0.040 |
Why?
|
Cervical Length Measurement | 1 | 2020 | 47 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2018 | 2732 | 0.040 |
Why?
|
Placenta | 2 | 2023 | 1725 | 0.040 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2023 | 1133 | 0.040 |
Why?
|
Monocytes | 2 | 2019 | 2603 | 0.040 |
Why?
|
Pyrimidines | 2 | 2023 | 3048 | 0.040 |
Why?
|
Anthropometry | 2 | 2016 | 1345 | 0.040 |
Why?
|
Neutropenia | 2 | 2017 | 893 | 0.040 |
Why?
|
Nucleosides | 1 | 2019 | 131 | 0.040 |
Why?
|
Molecular Sequence Data | 4 | 2013 | 17629 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2020 | 14752 | 0.040 |
Why?
|
Follow-Up Studies | 6 | 2019 | 39394 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7609 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2021 | 753 | 0.040 |
Why?
|
Dogs | 1 | 2023 | 3845 | 0.040 |
Why?
|
Contact Tracing | 1 | 2020 | 275 | 0.040 |
Why?
|
Chromosomes, Human | 1 | 2019 | 438 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2015 | 5375 | 0.040 |
Why?
|
Selection Bias | 1 | 2019 | 360 | 0.040 |
Why?
|
Government Programs | 1 | 2019 | 278 | 0.040 |
Why?
|
Biometry | 1 | 2020 | 570 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 10400 | 0.040 |
Why?
|
Calibration | 1 | 2020 | 822 | 0.040 |
Why?
|
Pregnancy Trimester, Second | 1 | 2020 | 736 | 0.030 |
Why?
|
Thailand | 1 | 2017 | 288 | 0.030 |
Why?
|
Epitopes | 1 | 2023 | 2529 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2009 | 3492 | 0.030 |
Why?
|
Triage | 1 | 2023 | 997 | 0.030 |
Why?
|
Fetal Death | 1 | 2018 | 434 | 0.030 |
Why?
|
Survival Analysis | 3 | 2017 | 10115 | 0.030 |
Why?
|
Inpatients | 2 | 2019 | 2569 | 0.030 |
Why?
|
Bayes Theorem | 2 | 2017 | 2360 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1757 | 0.030 |
Why?
|
Aspartate Aminotransferases | 1 | 2017 | 414 | 0.030 |
Why?
|
Drug Resistance | 1 | 2022 | 1599 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2022 | 5544 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2020 | 2179 | 0.030 |
Why?
|
United Nations | 1 | 2016 | 151 | 0.030 |
Why?
|
Base Sequence | 2 | 2019 | 12430 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 18068 | 0.030 |
Why?
|
Risk | 2 | 2018 | 9621 | 0.030 |
Why?
|
Escherichia coli | 2 | 2017 | 4213 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2017 | 606 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2020 | 863 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2022 | 1344 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 857 | 0.030 |
Why?
|
World Health Organization | 1 | 2020 | 1328 | 0.030 |
Why?
|
Drug Resistance, Microbial | 1 | 2017 | 830 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3441 | 0.030 |
Why?
|
Immunization, Passive | 1 | 2016 | 619 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 2089 | 0.030 |
Why?
|
Infant, Low Birth Weight | 1 | 2018 | 872 | 0.030 |
Why?
|
Brazil | 1 | 2017 | 1250 | 0.030 |
Why?
|
Awareness | 1 | 2018 | 653 | 0.030 |
Why?
|
Contraceptives, Oral | 1 | 2016 | 561 | 0.030 |
Why?
|
Virus Replication | 1 | 2021 | 2458 | 0.030 |
Why?
|
Health Status Disparities | 1 | 2025 | 1886 | 0.030 |
Why?
|
Intention | 1 | 2016 | 348 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 3813 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12095 | 0.030 |
Why?
|
Social Stigma | 1 | 2019 | 788 | 0.030 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2015 | 340 | 0.030 |
Why?
|
Ultrasonography, Prenatal | 1 | 2020 | 1771 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 641 | 0.030 |
Why?
|
Pregnancy Proteins | 1 | 2013 | 222 | 0.020 |
Why?
|
Gene Frequency | 1 | 2019 | 3626 | 0.020 |
Why?
|
Birth Certificates | 1 | 2011 | 71 | 0.020 |
Why?
|
Specimen Handling | 1 | 2016 | 708 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2021 | 2027 | 0.020 |
Why?
|
Caregivers | 1 | 2024 | 2308 | 0.020 |
Why?
|
Geography | 1 | 2013 | 654 | 0.020 |
Why?
|
Genetic Variation | 2 | 2019 | 6611 | 0.020 |
Why?
|
Placebos | 1 | 2015 | 1667 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 8055 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1076 | 0.020 |
Why?
|
India | 1 | 2017 | 2334 | 0.020 |
Why?
|
Community Health Services | 1 | 2016 | 659 | 0.020 |
Why?
|
Algorithms | 3 | 2020 | 14201 | 0.020 |
Why?
|
Family Characteristics | 1 | 2016 | 1004 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2020 | 6086 | 0.020 |
Why?
|
Goals | 1 | 2016 | 717 | 0.020 |
Why?
|
Health Personnel | 2 | 2020 | 3383 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1381 | 0.020 |
Why?
|
Lactation | 1 | 2012 | 392 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2012 | 13427 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2012 | 491 | 0.020 |
Why?
|
Developing Countries | 2 | 2015 | 2911 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 560 | 0.020 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2012 | 352 | 0.020 |
Why?
|
Neoplasms | 2 | 2015 | 22389 | 0.020 |
Why?
|
Body Height | 1 | 2016 | 1569 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2023 | 3238 | 0.020 |
Why?
|
Spouses | 1 | 2011 | 286 | 0.020 |
Why?
|
Health Care Costs | 1 | 2022 | 3270 | 0.020 |
Why?
|
Sex Factors | 2 | 2014 | 10633 | 0.020 |
Why?
|
Seasons | 1 | 2014 | 1524 | 0.020 |
Why?
|
Virus Internalization | 1 | 2012 | 503 | 0.020 |
Why?
|
Perinatal Care | 1 | 2011 | 246 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2013 | 645 | 0.020 |
Why?
|
Sequence Homology | 1 | 2008 | 199 | 0.020 |
Why?
|
Capsid Proteins | 1 | 2011 | 468 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2012 | 2749 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8748 | 0.020 |
Why?
|
Kenya | 1 | 2011 | 758 | 0.020 |
Why?
|
Body Size | 1 | 2011 | 463 | 0.020 |
Why?
|
Unsafe Sex | 1 | 2010 | 239 | 0.020 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2011 | 827 | 0.020 |
Why?
|
Blood Pressure | 1 | 2023 | 8544 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2011 | 752 | 0.020 |
Why?
|
Campylobacter jejuni | 1 | 2007 | 24 | 0.020 |
Why?
|
Peru | 1 | 2011 | 891 | 0.020 |
Why?
|
Drug Tolerance | 1 | 2009 | 365 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5891 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3671 | 0.020 |
Why?
|
Haemophilus influenzae | 1 | 2007 | 177 | 0.020 |
Why?
|
Lactates | 1 | 2007 | 401 | 0.020 |
Why?
|
Family Planning Services | 1 | 2010 | 279 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2007 | 575 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2011 | 878 | 0.020 |
Why?
|
Risk Assessment | 2 | 2018 | 24333 | 0.020 |
Why?
|
Motivation | 1 | 2016 | 2025 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2016 | 2200 | 0.020 |
Why?
|
South Africa | 1 | 2011 | 1872 | 0.020 |
Why?
|
Point Mutation | 1 | 2011 | 1596 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1305 | 0.020 |
Why?
|
Bacteria | 1 | 2016 | 2216 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2007 | 1065 | 0.020 |
Why?
|
Logistic Models | 2 | 2013 | 13318 | 0.020 |
Why?
|
Demography | 1 | 2010 | 1642 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2015 | 2121 | 0.020 |
Why?
|
Body Weight | 1 | 2016 | 4628 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2017 | 16053 | 0.010 |
Why?
|
Medication Adherence | 1 | 2017 | 2192 | 0.010 |
Why?
|
Surgical Wound Infection | 1 | 2014 | 1547 | 0.010 |
Why?
|
Aged | 4 | 2023 | 171786 | 0.010 |
Why?
|
Community Health Centers | 1 | 2008 | 469 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1803 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2017 | 7148 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2013 | 1890 | 0.010 |
Why?
|
Research Design | 1 | 2020 | 6214 | 0.010 |
Why?
|
Pregnancy Trimester, Third | 1 | 2007 | 586 | 0.010 |
Why?
|
Helicobacter pylori | 1 | 2007 | 380 | 0.010 |
Why?
|
Host-Pathogen Interactions | 1 | 2012 | 1469 | 0.010 |
Why?
|
Immunoglobulin A | 1 | 2007 | 992 | 0.010 |
Why?
|
Sequence Analysis, RNA | 1 | 2011 | 2041 | 0.010 |
Why?
|
Labor, Obstetric | 1 | 2007 | 323 | 0.010 |
Why?
|
Animals | 3 | 2023 | 169335 | 0.010 |
Why?
|
Sexually Transmitted Diseases | 1 | 2009 | 668 | 0.010 |
Why?
|
Immunologic Factors | 1 | 2012 | 1597 | 0.010 |
Why?
|
Focus Groups | 1 | 2009 | 1462 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2007 | 1836 | 0.010 |
Why?
|
Marital Status | 1 | 2003 | 426 | 0.010 |
Why?
|
Streptococcus pneumoniae | 1 | 2007 | 764 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16731 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 2493 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2007 | 1478 | 0.010 |
Why?
|
Occupations | 1 | 2003 | 516 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2012 | 5151 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 2714 | 0.010 |
Why?
|
Acute Disease | 1 | 2009 | 7245 | 0.010 |
Why?
|
Health Promotion | 1 | 2010 | 2210 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18435 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12801 | 0.010 |
Why?
|
Educational Status | 1 | 2003 | 2515 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2006 | 6856 | 0.010 |
Why?
|
Patient Selection | 1 | 2007 | 4265 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2007 | 4568 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 30046 | 0.010 |
Why?
|
United States | 2 | 2011 | 73186 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2011 | 15951 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2017 | 59739 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 12253 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2014 | 15661 | 0.000 |
Why?
|